Literature DB >> 6315977

Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates.

J Sullivan-Bolyai, H F Hull, C Wilson, L Corey.   

Abstract

The incidence of neonatal herpes simplex virus (HSV) infection in King County, Washington, has increased progressively from a rate of 2.6 per 100,000 live births to King County residents during the years 1966 through 1969 to 4.8, 7.4, and 11.9 cases per 100,000 live births for the years 1970 through 1973, 1974 through 1977, and 1978 through 1981, respectively. Detailed interviews of the parents of newborns with neonatal HSV-2 infection revealed clinically symptomatic genital herpes in the mother or father in 65% of the parents and serological and/or cultural evidence of HSV-2 infection in the mother in the other 35% of cases. Clinically symptomatic first episodes of genital herpes during pregnancy occurred in four of the mothers who were delivered of newborns with neonatal HSV-2 infection; two of the mothers were symptomatic at the time of birth. The other 16 interviewed mothers who delivered newborns with neonatal HSV-2 infection all had serological and/or cultural evidence of past HSV-2 infection but were asymptomatic at term. All six newborns with neonatal HSV-1 infection acquired the disease from nongenital sources, and two newborns seemed to have acquired the disease from nonmaternal sources. These data indicate that detailed interviews of the parents are often useful in increasing the clinician's index of suspicion for neonatal HSV infection. The increased prevalence of genital HSV infection in the United States seems to be associated with a concomitant increase in neonatal HSV infection.

Entities:  

Mesh:

Year:  1983        PMID: 6315977

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  19 in total

1.  Neonatal herpes prevention: a minor public health problem in some communities.

Authors:  A Mindel; J Taylor; R L Tideman; C Seifert; G Berry; K Wagner; J Page; C Marks; B Trudinger; A Cunningham
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Genotyping of herpes simplex viruses by polymerase chain reaction.

Authors:  H Piiparinen; A Vaheri
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  Preventing neonatal herpes?

Authors:  D E Mercey; A Mindel
Journal:  Genitourin Med       Date:  1991-02

4.  Periodic health examination, 1989 update: 4. Intrapartum electronic fetal monitoring and prevention of neonatal herpes simplex. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1989-12-15       Impact factor: 8.262

5.  Calcification in the adrenal glands associated with disseminated herpes simplex infection.

Authors:  S C Morrison; E Comisky; B D Fletcher
Journal:  Pediatr Radiol       Date:  1988

6.  Discrimination of herpes simplex virus types 1 and 2 cerebral infections in a rat model.

Authors:  T Bergström; B Svennerholm; N Conradi; P Horal; A Vahlne
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Hematogenous vertical transmission of herpes simplex virus type 1 in mice.

Authors:  Javier S Burgos; Carlos Ramirez; Fernando Guzman-Sanchez; Juan M Alfaro; Isabel Sastre; Fernando Valdivieso
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 8.  Sexually transmitted diseases in children: herpes simplex virus infection, cytomegalovirus infection, hepatitis B virus infection and molluscum contagiosum.

Authors:  A Nageswaran; G R Kinghorn
Journal:  Genitourin Med       Date:  1993-08

9.  Type specificity of complement-fixing antibody against herpes simplex virus type 2 AG-4 early antigen in patients with asymptomatic infection.

Authors:  C H Sherlock; R L Ashley; M L Shurtleff; K D Mack; L Corey
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

Review 10.  Neonatal herpes simplex infection.

Authors:  David W Kimberlin
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.